Fractalkine-CX3CR1 Axis in Periodontal Therapy

Giresun University90 enrolled

Overview

This study aimed to evaluate gingival crevicular fluid (GCF) levels of fractalkine/CX3CL1 and CX3CR1 in patients with gingivitis and periodontitis before and after non-surgical periodontal therapy.

Thirty stage 3 periodontitis, thirty gingivitis and thirty periodontally healthy individuals were enrolled in the study. Clinical periodontal measurements were recorded; gingivitis and periodontitis patients underwent non-surgical periodontal treatment, and GCF samples were collected at baseline and at 1 and 3 months after treatment. CX3CL1 and CX3CR1 were determined by ELISA.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

DOUBLE

Enrollment

Conditions

Periodontitis Gingivitis Inflammation Biomarkers

Interventions

Non-surgical periodontal treatmentOTHER

Scaling and root planing, oral hygiene education and motivation.

Eligibility

Sex: ALLMin age: 25 YearsMax age: 47 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. 25-50 years of age 2. having at least 20 natural teeth, excluding third molars 3. having no systemic disease 4. non-smokers 5. criteria for healthy control group: BOP \< 10% and PD ≤ 3 mm without clinical attachment loss or radiographic sign of alveolar bone destruction 6. criteria for stage 3 periodontitis group: interdental CAL ≥ 5 mm at least 2 non-adjacent teeth, PD ≥ 6 mm and radiographic bone loss extending to the mid-third of the root or beyond. Exclusion Criteria: 1. having any systemic diseases, 2. smoking 3. current pregnancy or lactation 4. a history of periodontal treatment in the past 6 months 5. using antibiotic, anti-inflammatory drugs or any other drugs within the past 6 months.

Locations (1)

Giresun University

Giresun, Turkey, Turkey (Türkiye)

Outcomes

Primary Outcomes

Changes in the levels of biochemical parameters

The levels of Fractalkine and CX3CR1 before and after periodontal treatment in gingivitis and periodontitis patients.

Time frame: Baseline and 1 and 3 months after treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.